Search Within

Robert Motzer

Formats
  1. Journal Article (610)
  2. Meeting Abstract (580)
  3. Book Section (20)
  4. Review (13)
  5. Correspondence (7)
  6. Conference Paper (6)
  7. Guidelines (5)
  8. Research Letter (5)
  9. Editorial (4)
  10. Book Whole (2)
Groups
  1. Department of Medicine (1252)
  2. Genitourinary Oncology Service (1252)
  3. Solid Tumor Oncology Division (1252)
  4. Surgery (292)
  5. Urology (283)
  6. Survivorship Research (254)

More Groups

People
  1. George Bosl (182)
  2. Martin Voss (178)
  3. Darren Feldman (158)
  4. Dean Bajorin (128)
  5. Paul Russo (119)
  6. Joel Sheinfeld (110)

More People

Years
  1. 2025 (35)
  2. 2024 (49)
  3. 2023 (47)
  4. 2022 (64)
  5. 2021 (65)
  6. 2020 (65)

More Years

Publications
  1. Journal of Clinical Oncology (448)
  2. Annals of Oncology (81)
  3. BJU International (40)
  4. Cancer (35)
  5. European Journal of Cancer (34)
  6. Clinical Cancer Research (33)

More Publications

Publishers
  1. American Society of Clinical Oncology (451)
  2. Oxford University Press (112)
  3. Elsevier Science, Inc. (111)
  4. Elsevier Inc. (89)
  5. Wiley Blackwell (87)
  6. American Association for Cancer Research (58)

More Publishers

Results (1252)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Association between biomarkers and clinical outcomes of lenvatinib + pembrolizumab in advanced renal cell carcinoma (RCC): Results from Study 111/KEYNOTE-146
    Meeting Abstract

    Lee, C. H.; Rasco, D. W.; Rao, A.; Taylor, M. H.; Hsieh, J. J.; Pinto, A.; Vogelzang, N. J.; Cao, Z. A.; Suttner, L.; Loboda, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase II study of talazoparib and avelumab in VHL deficient clear cell renal cell carcinoma
    Meeting Abstract

    Kotecha, R.; Lee, C. H.; McHugh, D. J.; Dadoun, C.; Knezevic, A.; Carlo, M. I.; Feld, E.; Shapnik, N.; Shah, N. J.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) in previously untreated patients with advanced renal cell carcinoma (aRCC): CheckMate 9ER updated results
    Meeting Abstract

    Cella, D.; Motzer, R. J.; Blum, S. I.; Ejzykowicz, F.; Hamilton, M.; Wallace, J.; Zhang, J.; Simsek, B.; Ivanescu, C.; Choueiri, T. K.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor
    Meeting Abstract

    Choueiri, T. K.; Albiges, L.; Hammers, H. J.; McKay, R. R.; Heng, D. Y. C.; Beckermann, K.; Kasturi, V.; Motzer, R. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214: Five-year follow-up results
    Meeting Abstract

    Cella, D.; Choueiri, T. K.; Hamilton, M.; Ejzykowicz, F.; Blum, S. I.; Ivanescu, C.; Motzer, R. J.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Patient-reported outcomes: What really matters to patients? – Authors' reply
    Correspondence

    Cella, D.; Choueiri, T.K.; Motzer, R. J.
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies
    Review

    Motzer, R. J.; Taylor, M. H.; Evans, T. R. J.; Okusaka, T.; Glen, H.; Lubiniecki, G. M.; Dutcus, C.; Smith, A. D.; Okpara, C. E.; Hussein, Z.; more...
    Expert Review of Anticancer Therapy (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: Extended follow-up results from JAVELIN Renal 101
    Journal Article

    Tomita, Y.; Motzer, R. J.; Choueiri, T. K.; Rini, B. I.; Miyake, H.; Uemura, H.; Albiges, L.; Fujii, Y.; Umeyama, Y.; Wang, J.; more...
    ESMO Open (2022)

    Fulltext@MSK | Save
  • Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
    Journal Article

    Chowell, D.; Yoo, S. K.; Valero, C.; Pastore, A.; Krishna, C.; Lee, M.; Hoen, D.; Shi, H.; Kelly, D. W.; Patel, N.; more...
    Nature Biotechnology (2022)

    Fulltext@MSK | Save
  • Biomarker analysis from CheckMate 214: Nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
    Journal Article

    Motzer, R. J.; Choueiri, T. K.; McDermott, D. F.; Powles, T.; Vano, Y. A.; Gupta, S.; Yao, J.; Han, C.; Ammar, R.; Papillon-Cavanagh, S.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save